BaroFold, Inc.

A Two-Stage Phase 1 Repeat Dose Study of BaroFeron* (Recombinant Human Interferon beta-1b) Compared to Betaferon® for Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Subcutaneous Administration in Healthy Volunteers